関連する実験動画

Updated: May 10, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

16.8K

ナノ粒子がん薬の開発者を懸念する破産申請

Heidi Ledford

    Nature
    |May 20, 2016
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
    07:59

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

    Published on: March 4, 2017

    9.5K
    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
    09:34

    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

    Published on: February 9, 2019

    9.5K

    関連する実験動画

    Last Updated: May 10, 2026

    Manufacture and Drug Delivery Applications of Silk Nanoparticles
    09:03

    Manufacture and Drug Delivery Applications of Silk Nanoparticles

    Published on: October 8, 2016

    16.8K
    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
    07:59

    A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

    Published on: March 4, 2017

    9.5K
    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
    09:34

    Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

    Published on: February 9, 2019

    9.5K

    関連する概念動画

    Preclinical Development: Overview01:28

    Preclinical Development: Overview

    Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    JoVEについて
    概要リーダーシップブログJoVEヘルプセンター
    著者向け
    出版プロセス編集委員会範囲と方針査読よくある質問投稿
    図書館員向け
    推薦の声購読アクセスリソース図書館諮問委員会よくある質問
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
    利用規約
    プライバシーポリシー
    ポリシー
    Jove
    Visualize
    お問い合わせ